Chinese Academy of Medical Sciences
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2004-07-08
- Employees
- -
- Market Cap
- -
Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma
Phase 1
Completed
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- Drug: Sintilimab+IBI305
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT04072679
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese ACademy of Medical Sciences and Peking Union Medical College, Beijing, China
Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )
Phase 2
- Conditions
- Breast CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2019-07-25
- Last Posted Date
- 2019-07-25
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT04033172
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.
Phase 2
- Conditions
- TP53 MutationDiffuse Large B-Cell LymphomaSintilimab
- Interventions
- Drug: Sintilimab-R-CHOP
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT04023916
Monitoring Efficacy of Radiotherapy in Lung Cancer and Esophageal Cancer
- Conditions
- Lung CancerEsophageal Cancer
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 150
- Registration Number
- NCT04014465
- Locations
- 🇨🇳
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical sciences, Beijing, Beijing, China
PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer
Phase 1
- Conditions
- Extensive-stage Small Cell Lung CancerRadiotherapyImmunotherapy
- Interventions
- Drug: PD-1 inhibitor JS-001
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 6
- Registration Number
- NCT03971214
- Locations
- 🇨🇳
Cancer Insititute and Hosiptal of Chinese Academy of Medical Sciences, Beijing, Beijing, China
Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR
- Conditions
- Recurrent or Metastatic Breast Cancer
- Interventions
- Diagnostic Test: cfDNA was detected by dPCR
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 200
- Registration Number
- NCT03947736
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer
Phase 2
- Conditions
- Hormone Receptor Positive Advanced Breast Cancer
- Interventions
- Drug: fluvestrant + oral vinorelbine
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT03939871
- Locations
- 🇨🇳
National Cacner Center/ Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT03933319
- Locations
- 🇨🇳
Peng Yuan, Beijing, Beijing, China
A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT03933982
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis
Phase 2
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Radiation: Stereotactic Body Radiotherapy
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT03927898
- Locations
- 🇨🇳
Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath